TEAD 4 Drives SKCM Progression Through COL 1 A 2 Transcriptional Activation and Modulation of AKT /m TOR Signalling and Necroptosis‐Related Phenotypes
Experimental Dermatology · 2026-06 · 35 (6)
DOI: 10.1111/exd.70288 ↗At a glance
Journal article in Experimental Dermatology, published online on 2026-06-06. Written by Jiaqiong Lin and 7 co-authors. Institution: Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Major MEDLINE topics: Transcription Factors, DNA-Binding Proteins, Melanoma, Collagen Type I. 45 references. Funded by: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (original language)
Skin cutaneous melanoma (SKCM) continues to pose significant therapeutic challenges owing to its aggressive nature and evolving resistance mechanisms. This study investigates the under‐characterized role of Hippo pathway effector TEAD4 in SKCM pathogenesis through integrated multiomics analysis of clinical cohorts (TCGA, GEO, immunotherapy cohorts) combined with functional validation in A375 cell models and xenograft systems. Our pan‐cancer analysis identified TEAD4 overexpression as a strong prognostic indicator associated with poor survival and a potential association with inferior immunotherapy response. Functional experiments in A375 cells and xenograft models showed that TEAD4 knockdown impaired proliferation, migration and tumour growth while increasing necroptosis‐related markers. Mechanistic investigation showed that TEAD4 directly binds the COL1A2 promoter and promotes its transcription. In A375 cells, COL1A2 overexpression attenuated TEAD4 knockdown‐induced changes in AKT/mTOR signalling, necroptosis‐related markers and malignant phenotypes. These findings support a TEAD4 and COL1A2 regulatory model associated with SKCM progression, AKT/mTOR pathway activity and necroptosis‐related phenotypes, and suggest TEAD4 as a prognostic factor and potential biomarker associated with immunotherapy outcome that requires further validation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Dongguan Maternal and Child Health Care Hospital, Postdoctoral Innovation Practice Base of Southern Medical University, Dongguan, China.
- Department of Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China.
- Department of Medical Genetics/Experimental Education/Administration Center, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
- Gaozhou People's Hospital, Gaozhou, China.
- The First Clinical Medical School of Nanfang Hospital, Southern Medical University, Guangzhou, China.
ORCID profiles: Jiaqiong Lin, Fei He, Fu Xiong
Funding
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Cite
APA
Lin, J., Zheng, Y., Shen, Z., Liu, Q., Liang, F., He, F., Li, X., & Xiong, F. (2026). TEAD 4 Drives SKCM Progression Through COL 1 A 2 Transcriptional Activation and Modulation of AKT /m TOR Signalling and Necroptosis‐Related Phenotypes. Experimental Dermatology, 35(6). https://doi.org/10.1111/exd.70288
Vancouver
Lin J, Zheng Y, Shen Z, Liu Q, Liang F, He F, et al. TEAD 4 Drives SKCM Progression Through COL 1 A 2 Transcriptional Activation and Modulation of AKT /m TOR Signalling and Necroptosis‐Related Phenotypes. Experimental Dermatology. 2026;35(6). doi:10.1111/exd.70288
BibTeX
@article{Lin2026,
author = {Lin, Jiaqiong and Zheng, Yingchun and Shen, Zongrui and Liu, Qian and Liang, Fangkeng and He, Fei and Li, Xiaoyong and Xiong, Fu},
title = {TEAD 4 Drives SKCM Progression Through COL 1 A 2 Transcriptional Activation and Modulation of AKT /m TOR Signalling and Necroptosis‐Related Phenotypes},
journal = {Experimental Dermatology},
year = {2026},
volume = {35},
number = {6},
doi = {10.1111/exd.70288}
}
EUVIMED